-
公开(公告)号：US20240350657A1
公开(公告)日：2024-10-24
申请号：US18622613
申请日：2024-03-29
CPC分类号： A61K47/6889 , A61K38/07 , A61K38/12 , A61K47/545 , A61K47/68031 , A61K47/6809 , A61K47/6811 , A61K47/6849 , A61P35/00
摘要： The present invention relates to a linker of the following formula (I) or a salt thereof:
The present invention relates to a linker-drug conjugate of the following formula (II) or a salt thereof:
The present invention relates also to a binding unit-drug conjugate, such as an antibody-drug conjugate, of the following formula (III) or (IV) or a salt thereof:
as well as a pharmaceutical composition comprising such a binding unit-drug conjugate and its use in the treatment of cancer.-
公开(公告)号：US12011485B2
公开(公告)日：2024-06-18
申请号：US17280800
申请日：2019-09-27
CPC分类号： A61K47/6849 , A61K38/07 , A61K38/12 , A61K47/545 , A61K47/6809 , A61K47/6811 , A61P35/00
摘要： The present invention relates to a linker of the following formula (I) or a salt thereof: (I). The present invention relates to a linker-drug conjugate of the following formula (II) or a salt thereof: (II). The present invention relates also to a binding unit-drug corrugate, such as an antibody-drug conjugate, of the following formula (III) or (IV) or a salt thereof: (III), (IV), as well as a pharmaceutical composition comprising such a binding unit-drug corrugate and its use in the treatment of cancer.
-
公开(公告)号：US11873339B2
公开(公告)日：2024-01-16
申请号：US16908347
申请日：2020-06-22
发明人： John Lippincott , Edward Thein Htun Van Der Horst , Sung Young Kim , Leonard G Presta , Jan-Willem Theunissen
IPC分类号： C07K16/28 , A61K39/395 , A61K47/68 , A61P35/00 , A61K31/4025 , A61K31/404 , A61K31/5517 , A61K39/00
CPC分类号： C07K16/2827 , A61K31/404 , A61K31/4025 , A61K31/5517 , A61K39/39558 , A61K47/6803 , A61K47/6851 , A61K47/6873 , A61P35/00 , A61K2039/505 , C07K2317/24 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/74 , C07K2317/92
摘要： The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
-
公开(公告)号：US11661457B2
公开(公告)日：2023-05-30
申请号：US16801491
申请日：2020-02-26
发明人： Ian Rilatt , Michel Perez , Liliane Goetsch , Matthieu Broussas , Charlotte Beau-Larvor , Jean-Francois Haeuw , Thierry Champion , Alain Robert , Marie Lamothe
CPC分类号： C07K16/2863 , A61K47/6803 , A61K47/6849
摘要： The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.
-
公开(公告)号：US20220218838A1
公开(公告)日：2022-07-14
申请号：US17609129
申请日：2020-05-06
IPC分类号： A61K47/68 , A61P35/00 , A61K47/54 , A61K31/704 , A61K31/675 , A61K31/7068 , A61K33/243 , A61K31/337 , A61K31/506 , A61K31/282 , A61K31/513 , A61K31/65 , A61K31/4184
摘要： The present invention relates to an ADC having the following formula (I) in which Ab is an anti-IGF1R antibody characterized in that it comprises light chain CDRs of sequences SEQ ID Nos. 9, 5 and 11, respectively, and heavy chain CDRs of sequences SEQ ID Nos. 7, 2 and 3, respectively, and n is between 1 and 12, for use in the treatment of proliferative diseases, such as cancer, characterized in that the ADC is administered concomitantly with or subsequent to docetaxel.
-
公开(公告)号：US20220071860A1
公开(公告)日：2022-03-10
申请号：US17415875
申请日：2019-12-19
摘要： The subject matter of the present invention is a novel composition in emulsion form comprising glycerol, vaseline, and liquid paraffin as well as a particular system of preservatives and gelling agents, wherein said composition is characterised by the absence of parabens.
-
7.发明授权公开(公告)号：US10881702B2
公开(公告)日：2021-01-05
申请号：US15998967
申请日：2017-02-17
发明人： Thien Nguyen , Arnaud Pillon
IPC分类号： A61K36/37 , A61P35/00 , A61K31/122 , A61K31/215
摘要： The invention relates to a compound selected from among celastrol, the derivatives thereof and the pharmaceutically acceptable salts of celastrol and its derivatives, or a composition comprising such a compound for use in the topical prevention and/or treatment of a tumour or precancerous disease of the skin.
-
公开(公告)号：US20200270352A1
公开(公告)日：2020-08-27
申请号：US16801491
申请日：2020-02-26
发明人： Ian RILATT , Michel PEREZ , Liliane GOETSCH , Matthieu BROUSSAS , Charlotte BEAU-LARVOR , Jean-Francois HAEUW , Thierry CHAMPION , Alain ROBERT , Marie LAMOTHE
摘要： The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.
-
公开(公告)号：US20200040102A1
公开(公告)日：2020-02-06
申请号：US16519411
申请日：2019-07-23
摘要： The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
-
公开(公告)号：US10548885B2
公开(公告)日：2020-02-04
申请号：US15310415
申请日：2015-07-09
IPC分类号： A61K31/4545 , A61K9/00 , A61K47/38
摘要： The present invention relates to a method of treatment of movement disorders, comprising administering to a patient in need thereof an effective amount of befiradol, where in the administering step provides an average patient's maximum plasma concentration of befiradol below 15 ng/mL which occurs more than 4 hours post administration, said method minimizing side effects of dizziness and nausea. Sustained release pharmaceutical compositions that can be used according to this method are also described.
-
-
-
-
-
-
-
-
-
搜索结果
453 条记录 (耗时 0.041 秒)
